Studies have found that the anti-lipolytic effect of insulin can be adjusted through the AKT/PKA/HSL signaling pathway (Yin et al., 2019), and inhibiting excessive lipolysis of adipose tissue (Park et al., 2020) is an important way to treat metabolic diseases. Here, AKT1 is linked to metabolic disease.